Why join the MMA program?
Reduce the time for methylmalonic acidemia drug development
All your medical data in one place
Follow new clinical trials
Make your de-identified health information part of multiple research projects
Our work with MMA research
Methylmalonic acidemia (MMA) is a genetic condition where individuals cannot break down certain proteins and fats. The symptoms of MMA typically begin very early in life and vary from mild to severe. Those with MMA can experience vomiting, dehydration, fatigue, low muscle tone, and difficulty gaining weight. Developmental delay, intellectual disability, and damage to the kidneys, pancreas, liver, and brain can also occur. MMA requires lifelong management and in some cases, can be life-threatening. There is currently no cure.
How it works
1. Sign up
Create your private account and review our research consent (takes about 10 minutes)
2. We get to work
We do all the behind-the-scenes work to retrieve and process your records
3. Empower research
Track your contribution to research projects and, based on your records, find out if you qualify for new clinical trials based on your records
Our values & principles.
We believe that the only way to keep data accessible to the researchers who need it is by enabling patients to own and control their own data. Patients decide for themselves whether they want to privately and securely contribute to research, rather than having the decision made on their behalf.
We aim to make useful data accessible to all researchers who have legitimate research questions or research programs. For academic research, we offer access without charge. We take research ethics seriously, and we have policies in place to ensure that research is conducted with integrity.
We don’t like to take sides—we give all members of the community the option to get involved. Success in rare disease research takes a village and we always welcome additional collaborators who can advance and benefit from the mission.
Our primary mission is to accelerate drug development, so we prioritize generating insights specifically relevant to therapeutic research. We invest deeply in quality, security, and compliance to make this a reality.